09:11 AM EDT, 06/11/2024 (MT Newswires) -- Health care stocks were mixed premarket Tuesday, with the Health Care Select Sector SPDR Fund ( XLV ) was 0.1% higher and the iShares Biotechnology ETF ( IBB ) was down 0.5% recently.

Viridian Therapeutics ( VRDN ) advanced more than 6% after saying it will begin two late-stage clinical trials to evaluate VRDN-003 in patients with active and chronic thyroid eye disease in August.

ProKidney ( PROK ) was down more than 15% after it launched an underwritten public offering and a concurrent registered direct offering of up to $125 million of its class A shares.

Arcutis Biotherapeutics ( ARQT ) was more than 2% higher after saying its experimental roflumilast cream 0.15% showed continued improvements in the signs and symptoms of atopic dermatitis, including itch, through 56 weeks of treatment.